Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

EU Committee Backs Zeffix For Chronic Hepatitis B LAVAL, Quebec -- April 27, 1999 -- The European Union’s Committee for Proprietary Medicinal Products (CPMP) has given a positive opinion on Zeffix, the world’s first oral antiviral treatment for chronic hepatitis B, recommending its approval in the European Union. Zeffix was developed by BioChem Pharma Inc. and is being marketed by Glaxo Wellcome. The CPMP has recommended the approval of Zeffix for a broad group of chronic hepatitis B patients. The recommendation, which comes under the CPMP’s classification known as "exceptional circumstances", asks that Glaxo Wellcome continues to supply the approval agency with additional data on specific patient sub-groups over the coming years. The European Commission will make a final decision after considering the committee’s opinion. The marketing application for Zeffix was submitted to the European Medicines Evaluation Agency (EMEA) in March 1998 under the centralized procedure, through which a single license is granted for all 15 member states of the European Union. According to World Health Organization data, approximately 350 million people around the world are long-term (chronic) carriers of the hepatitis B virus (HBV), including an estimated four million people in the European Union. Zeffix is available in the Philippines, Hong Kong, Canada (as Heptovir), the USA (as Epivir-HBV), and Switzerland, and approved in China (as Heptodin), Thailand, Pakistan, New Zealand and Argentina. Regulatory applications to market Zeffix for chronic hepatitis B treatment have been submitted worldwide, including in Korea, Taiwan and Japan. E-mail this page to a friend or colleague! To print, use this version